Literature DB >> 20440625

Reduction of parasitism tissue by treatment of mice chronically infected with Trypanosoma cruzi with lignano lactones.

Viviane Rodrigues Esperandim1, Daniele da Silva Ferreira, Juliana Saraiva, Márcio Luis Andrade Silva, Eveline Soares Costa, Ana Carolina Pereira, Jairo Kenupp Bastos, Sérgio de Albuquerque.   

Abstract

The reduction of parasitism tissue upon treatment with two lignano lactones, namely (-)- cubebin (CUB) and (-)-hinokinin (HNK), was evaluated in the chronic phase of Chagas' disease by quantifying the enzyme beta-galactosidase expressed by the CL B5 clone strain of Trypanosoma cruzi. Tissue karyometry was also performed. Treatment with the assessed lignans led to a larger reduction in parasitism tissue in all evaluated organs, compared with benznidazole (BZN). Oral treatment with CUB or HNK was more effective. Karyometry results demonstrated that the infected control animals had increased nuclear area compared with uninfected controls, indicating cellular hypertrophy. Results also revealed that use of CUB or HNK was able to significantly prevent this increase, and a slight decrease in the nuclear area was observed, compared with mice treated with BZN. Taken together, these data demonstrate that CUB and HNK could be considered as potential compounds for the development of new drugs for treatment of Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20440625     DOI: 10.1007/s00436-010-1885-z

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  26 in total

Review 1.  An overview of Chagas disease treatment.

Authors:  Jean Jannin; Luis Villa
Journal:  Mem Inst Oswaldo Cruz       Date:  2007-11-05       Impact factor: 2.743

2.  Is nitric oxide involved in the tolerance of Calomys callosus as a reservoir host towards Trypanosoma cruzi infection?

Authors:  C K Dost; J Saraiva; U Zentgraf; N Monesi; W Engels; S Albuquerque
Journal:  J Infect       Date:  2006-01       Impact factor: 6.072

3.  Parasite persistence correlates with disease severity and localization in chronic Chagas' disease.

Authors:  L Zhang; R L Tarleton
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

4.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 5.  The pathogenesis of Chagas' disease: when autoimmune and parasite-specific immune responses meet.

Authors:  M B Soares; L Pontes-De-Carvalho; R Ribeiro-Dos-Santos
Journal:  An Acad Bras Cienc       Date:  2001-12       Impact factor: 1.753

6.  In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi.

Authors:  Juliana Saraiva; Celeste Vega; Mirian Rolon; Rosangela da Silva; Márcio Luis Andrade E Silva; Paulo Marcos Donate; Jairo Kenupp Bastos; Alícia Gomez-Barrio; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2006-10-12       Impact factor: 2.289

7.  [Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole].

Authors:  H de O Ferreira
Journal:  Rev Soc Bras Med Trop       Date:  1990 Oct-Dec       Impact factor: 1.581

8.  Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.

Authors:  F S Buckner; C L Verlinde; A C La Flamme; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

9.  Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes.

Authors:  M J O Toledo; M T Bahia; V M Veloso; C M Carneiro; G L L Machado-Coelho; C F Alves; H R Martins; R E Cruz; W L Tafuri; M Lana
Journal:  J Antimicrob Chemother       Date:  2004-04-21       Impact factor: 5.790

10.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

View more
  6 in total

Review 1.  Advances in Chagas disease drug development: 2009-2010.

Authors:  Frederick S Buckner; Nazlee Navabi
Journal:  Curr Opin Infect Dis       Date:  2010-12       Impact factor: 4.915

2.  In vivo infection by Trypanosoma cruzi: a morphometric study of tissue changes in mice.

Authors:  Viviane Rodrigues Esperandim; Daniele da Silva Ferreira; Karen Cristina Sousa Rezende; Wilson Roberto Cunha; Juliana Saraiva; Jairo Kenupp Bastos; Márcio Luis Andrade E Silva; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2012-07-27       Impact factor: 2.289

Review 3.  Medicinal Attributes of Lignans Extracted from Piper Cubeba: Current Developments.

Authors:  Regiane Godoy de Lima; Maria Teresa Barros; Rosangela da Silva Laurentiz
Journal:  ChemistryOpen       Date:  2018-02-02       Impact factor: 2.911

4.  Relevance of Trypanothione Reductase Inhibitors on Trypanosoma cruzi Infection: A Systematic Review, Meta-Analysis, and In Silico Integrated Approach.

Authors:  Andréa Aparecida Santos Mendonça; Camila Morais Coelho; Marcia Paranho Veloso; Ivo Santana Caldas; Reggiani Vilela Gonçalves; Antônio Lucio Teixeira; Aline Silva de Miranda; Rômulo Dias Novaes
Journal:  Oxid Med Cell Longev       Date:  2018-10-24       Impact factor: 6.543

Review 5.  An Ethnopharmacological, Phytochemical and Pharmacological Review on Lignans from Mexican Bursera spp.

Authors:  Maria Carla Marcotullio; Massimo Curini; Judith X Becerra
Journal:  Molecules       Date:  2018-08-08       Impact factor: 4.411

6.  Synergistic Effect of Lupenone and Caryophyllene Oxide against Trypanosoma cruzi.

Authors:  Glendy Polanco-Hernández; Fabiola Escalante-Erosa; Karlina García-Sosa; María E Rosado; Eugenia Guzmán-Marín; Karla Y Acosta-Viana; Alberto Giménez-Turba; Efraín Salamanca; Luis M Peña-Rodríguez
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-20       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.